JPMorgan Chase & Co. Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

JPMorgan Chase & Co. lowered its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 51.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 268,050 shares of the specialty pharmaceutical company's stock after selling 286,785 shares during the period. JPMorgan Chase & Co. owned 1.27% of ANI Pharmaceuticals worth $14,818,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. US Bancorp DE grew its stake in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the period. KBC Group NV boosted its holdings in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $166,000. HighTower Advisors LLC bought a new position in ANI Pharmaceuticals during the third quarter worth $222,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after acquiring an additional 412 shares during the period. Institutional investors own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ANIP shares. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $79.75.

Remove Ads

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $197,792 over the last three months. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded up $0.83 during midday trading on Tuesday, hitting $69.55. 191,896 shares of the company's stock were exchanged, compared to its average volume of 268,605. The company has a market cap of $1.51 billion, a P/E ratio of -126.45 and a beta of 0.49. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a 50-day moving average price of $62.52 and a two-hundred day moving average price of $59.15. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.